These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11676280)

  • 1. Antibody-directed, effector cell-mediated tumor destruction.
    Sondel PM; Hank JA
    Hematol Oncol Clin North Am; 2001 Aug; 15(4):703-21. PubMed ID: 11676280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving the efficacy of antibody-based cancer therapies.
    Carter P
    Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction, expression, and characterization of anticarcinoma sFv fused to IL-2 or GM-CSF.
    Zhao L; Rai SK; Grosmaire LS; Ledbetter JA; Fell HP
    J Hematother Stem Cell Res; 1999 Aug; 8(4):393-9. PubMed ID: 10634177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
    Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
    Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.
    Alderson KL; Sondel PM
    J Biomed Biotechnol; 2011; 2011():379123. PubMed ID: 21660134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant antibody fusion proteins for cancer immunotherapy.
    Reisfeld RA; Gillies SD
    Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():27-53. PubMed ID: 8815009
    [No Abstract]   [Full Text] [Related]  

  • 7. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.
    Liljefors M; Nilsson B; Hjelm Skog AL; Ragnhammar P; Mellstedt H; Frödin JE
    Int J Cancer; 2003 Jul; 105(5):717-23. PubMed ID: 12740924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement and cellular cytotoxicity in antibody therapy of cancer.
    Wang SY; Weiner G
    Expert Opin Biol Ther; 2008 Jun; 8(6):759-68. PubMed ID: 18476787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.
    Fernández-Marrero Y; López-Requena A
    MAbs; 2011; 3(6):528-34. PubMed ID: 22123064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotoxin therapy of malignancy.
    Grossbard ML; Nadler LM
    Important Adv Oncol; 1992; ():111-35. PubMed ID: 1582669
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
    Surfus JE; Hank JA; Oosterwijk E; Welt S; Lindstrom MJ; Albertini MR; Schiller JH; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):184-91. PubMed ID: 8811493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current approaches in ovarian cancer vaccines.
    Reinartz S; Wagner U
    Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
    Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
    J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monoclonal antibody-based design of antitumor drugs: prerequisites and progress].
    Chmutin EF; Ivanov PK; Baryshnikov AIu
    Vestn Ross Akad Med Nauk; 2004; (12):10-6. PubMed ID: 15678682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2.
    Hooijberg E; Sein JJ; van den Berk PC; Hart AA; van der Valk MA; Kast WM; Melief CJ; Hekman A
    Cancer Res; 1995 Jun; 55(12):2627-34. PubMed ID: 7540106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors.
    Sharifi J; Khawli LA; Hu P; King S; Epstein AL
    Hybrid Hybridomics; 2001; 20(5-6):305-12. PubMed ID: 11839248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein.
    Bei R; Schlom J; Kashmiri SV
    J Immunol Methods; 1995 Oct; 186(2):245-55. PubMed ID: 7594624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies.
    Taylor RP; Lindorfer MA
    Semin Immunol; 2016 Jun; 28(3):309-16. PubMed ID: 27009480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering mouse monoclonal antibodies for cancer immunotherapy.
    Orlandi R
    Year Immunol; 1993; 7():69-73. PubMed ID: 8372514
    [No Abstract]   [Full Text] [Related]  

  • 20. Strategies for immunotherapy of cancer.
    Melief CJ; Toes RE; Medema JP; van der Burg SH; Ossendorp F; Offringa R
    Adv Immunol; 2000; 75():235-82. PubMed ID: 10879286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.